Researchers profiled the genotypes and phenotypes for more than 700 induced pluripotent stem cell lines, uncovering between-individual sources of variation.
The cell lines were edited with CRISPR/Cas9 to create fusions of GFP with the proteins of interest, allowing researchers to image structures in real time.
Thermo Fisher said the deal strengthens its portfolio for stem cell research, and it will fold MTI-GlobalStem into its life sciences solutions segment.
By analyzing the transcriptomes of more than 4,000 individual cells, researchers identified stem cell-like cellular subpopulations in six oligodendroglioma tumors.
